To observe the efficacy of 1565 nm nonablative fractional laser for the treatment of scar after trauma and to explore the optimum time for therapy.

Retrospective analysis was performed on 100 patients with scars who were treated with 1565 nm nonablative fraction laser for 3 times at 4 weeks interval. Five groups (≤3 d, 4-21 d, 22-90 d, 91-180 d) were divided according to the time of laser intervention after scar formation. The Patient and Observer Scar Assessment Scale (POSAS) was used to evaluate the efficacy by doctors and patients or family members of pediatric patients.

After 3 times of treatment, the scores of patients＇ scar vascularity, pigmentation, thickness, relief, pliability, surface area, and overall valuation in POSAS by doctors and the scores of pain, itch, color, stiffness, thickness, irregularity, and overall valuation in POSAS by patients or family members of pediatric patients were all significantly lower than those before the first combined treatment (t=9.488, 9.072, 6.204, 7.855, 5.812, 11.459, 11.168, 5.272, 7.628, 4.790, P<0.001). The overall evaluation scores by doctors were (4.70±1.56) and (1.30±0.80) points. Compared with group 4-21 d, the overall evaluation scores of physicians before and after treatment were not statistically different from those of the 4-21d group, but were significantly better than those of the 22-90 d group, the 91-180 d group, and the 181-365 d group. No serious adverse reactions were found in the treatment.

1565 nm nonablative fractional laser is an effective and safe treatment for immature scars, and the improvement is associated with intervention time.

Cicatrix; Lasers; Immature scar; Early intervention; Nonablative fractional laser; 1565 nm